I would appeal to any resident of the Grand Commonwealth of Kentucky to repost a personalized draft of one of the many letters posted on this board and the OTHER board. I think a couple of posters had some good ones from not too long ago and I hacked up one that "tsn" posted on the OTHER board:
“Senator Paul,
I'm addressing this to you both as a respected physician and honored Senator - I'm curious about the hold up regarding Leronlimab. It has met the thresholds for an Emergency Use Authorization as a treatment for Covid-19. It has been proven, using a multi-center, double blind, randomized, placebo controlled Phase II study, to be efficacious against SARS-CoV-2 in the the mild to moderate patient population in a study approved by the FDA. And, Leronlimab has a proven safety profile as demonstrated in studies of over 1,000 patients, for HIV and SARS-CoV-2.
In light of the retrospective and anecdotal evidence used to give Convalescent Plasma an Emergency Use Authorization for use as a treatment in a very narrow subset of early Covid-19 patients, I am left scratching my head as how a multi-center, double blind, randomized, placebo controlled study of any size could be negated by retrospective and non-blind, non-randomized, and non-use of placebos in uncontrolled studies of even the largest sample sizes (ie. 70,000 patient Mayo study).
I can attest to the fact that myself, and many Physicians and Healthcare Providers are feeling frustrated by what appears to be favoritism played towards large Pharmaceutical Companies who have staff working at the FDA as Consultants. While patients continue to die of inflammation related disorders due to the out-of-control immune response to the SARS-CoV-2 attack, it seems almost neglectful to offer Remdesivir for even broader conditions and supportive measures to such patients. An antiviral vaccine is supposed to be preventative, not used as a therapy for an already induced immune response. And, the use of steroids is contraindicated in patients not requiring oxygen. In addition, comparatively speaking, Leronlimab versus steroids, does not suppress the immune system, but enhances it, reducing viral load to zero as it reduces inflammation.
So, for mild to moderate patients, Leronlimab is proven to be the most effective against SARS-CoV-2 versus Remdesivir, Steroids and Convalescent Plasma. This patient population is important to treat early for many reasons besides just preventing potential worsening of progression towards serious illness. Our medical community has been overwhelmed by the large influx of SARS-CoV-2 patients, to the detriment of other serving other types of maladies, which include trauma as more people re-enter the workforce. Healthcare Providers need help in getting patients out of the hospitals as quickly as possible. Lest we not forget the cost savings of such measures.
I implore you look into Leronlimab and investigate why is has not been granted Emergency Use Authorization. It needs to be another tool Practitioners can rely on to bring the Pandemic under control!!
Sincerely and respectfully,
Joe Citizen of the Commonwealth of Kentucky“
News 
Market Data 
Discover 
AI
